NARBERTH, PA — Chou2 Pharma, LLC has announced the opening of a series of Investigational New Animal Drug (INAD) files with the Center for Veterinary Medicine (CVM). This move marks a significant step in the company’s mission to develop innovative cannabinoid-based therapies for companion animals, leveraging their precision formulating platform.
John Payne, Co-Founder and Executive Chairman of Chou2 Pharma, emphasized the importance of this development. “Opening these INAD files with CVM is an important first step toward our achieving our goal of advancing veterinary medicine with this class of molecules,” he stated. Payne highlighted the potential for their unique formulating platform to produce a groundbreaking portfolio of animal drugs.
Earlier this year, Chou2 Pharma appointed Brian Segebrecht as CEO to spearhead the expansion of their drug pipeline. Segebrecht brings a wealth of experience from his previous role as CEO of Sentrx Animal Care, where he successfully scaled the business to a strategic exit. He expressed enthusiasm for the potential of cannabinoids in veterinary medicine, noting, “The therapeutic potential of cannabinoid molecules in veterinary medicine is robust. Some of the most underserved therapeutic areas of companion animal veterinary medicine also happen to be the most receptive to treatment with this molecular class.”
Segebrecht’s leadership and passion for advancing therapies in underrepresented areas align with Chou2 Pharma’s strategic goals. The company aims to position itself at the forefront of veterinary medicine innovation, targeting specific therapeutic needs of companion animals with their proprietary cannabinoid formulations.
As Chou2 Pharma moves forward with its plans, the company is poised to make significant contributions to the field of veterinary medicine, providing new treatment options for pets and peace of mind for their owners.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.